These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37833461)

  • 1. DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway.
    Fan H; Liu W; Zeng Y; Zhou Y; Gao M; Yang L; Liu H; Shi Y; Li L; Ma J; Ruan J; Cao R; Jin X; Chen J; Cheng G; Yang H
    Commun Biol; 2023 Oct; 6(1):1041. PubMed ID: 37833461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.
    Dai M; Boudreault J; Wang N; Poulet S; Daliah G; Yan G; Moamer A; Burgos SA; Sabri S; Ali S; Lebrun JJ
    Cancer Res; 2021 Mar; 81(5):1332-1346. PubMed ID: 33372040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeling.
    Kundumani-Sridharan V; Singh NK; Kumar S; Gadepalli R; Rao GN
    J Biol Chem; 2013 Jul; 288(30):22150-62. PubMed ID: 23737530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
    Bockstaele L; Bisteau X; Paternot S; Roger PP
    Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.
    Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
    Front Immunol; 2021; 12():799171. PubMed ID: 35095879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CDK4 and CDK6: From Discovery to Therapy.
    Sherr CJ; Beach D; Shapiro GI
    Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
    Jia Y; Domenico J; Swasey C; Wang M; Gelfand EW; Lucas JJ
    PLoS One; 2014; 9(5):e97448. PubMed ID: 24848372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer.
    Sobhani N; Fassl A; Mondani G; Generali D; Otto T
    Cells; 2021 Feb; 10(2):. PubMed ID: 33535617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.
    Rodríguez-Díez E; Quereda V; Bellutti F; Prchal-Murphy M; Partida D; Eguren M; Kollmann K; Gómez de Cedrón M; Dubus P; Cañamero M; Martínez D; Sexl V; Malumbres M
    Blood; 2014 Oct; 124(15):2380-90. PubMed ID: 25157181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses
    Klein K; Witalisz-Siepracka A; Gotthardt D; Agerer B; Locker F; Grausenburger R; Knab VM; Bergthaler A; Sexl V
    Front Immunol; 2021; 12():650977. PubMed ID: 34248938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
    Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
    Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaempferol suppresses proliferation and induces apoptosis and DNA damage in human gallbladder cancer cells through the CDK4/CDK6/cyclin D1 pathway.
    Liu ZQ; Yao GL; Zhai JM; Hu DW; Fan YG
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1311-1321. PubMed ID: 33629301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
    Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
    Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases.
    Seok JK; Kim M; Kang HC; Cho YY; Lee HS; Lee JY
    Arch Pharm Res; 2023 Jun; 46(6):500-534. PubMed ID: 37354378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells.
    Liu Y; Zhao Y; Han C; Ren C
    Comput Math Methods Med; 2022; 2022():2402567. PubMed ID: 35535229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
    Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
    Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer.
    Storozynsky Q; Hitt MM
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
    Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
    Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK4 and CDK6 kinases: From basic science to cancer therapy.
    Fassl A; Geng Y; Sicinski P
    Science; 2022 Jan; 375(6577):eabc1495. PubMed ID: 35025636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
    Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
    J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.